Presentation for Mograflox (Moxifloxacin 0.5% eye drops) a Flouroquinolone used for the treatment of Keratitis, Conjunctivitis and corneal ulcers.

2. Let us take a look again on human eye structures

3. Drug description

6. Action & Clinical pharmacology

7. Moxifloxacin is a synthetic fluoroquinolone antibacterial agent active against a broad spectrum of Gram-positive and Gram-negative ocular pathogens. Mechanism of action

12. Mograflox®is also effective against: MRSA and Pseudomonas aeruginosa Moxifloxacin has a good activity against Pseudomonas aeruginosa. assisted by its excellent penetration power into the cornea which is much higher than Ciprofloxacin (used as a traditional therapy in Pseudomonas corneal ulcers before).

13. Contra-Indications

14. Mograflox®Ophthalmic solution is contraindicated in patients with a history of hypersensitivity to: Moxifloxacin Other quinolones Any of the components in this medication

15. Warnings

20. Drug-drug interaction studies have not been conducted with Mograflox®solution.

21. Side effects

24. The recommended dosage regimen for patients one year of age and older is one drop in the affected eye(s) 3 times a day for 7 days.

25. Pack & Price

26. Mograflox® is supplied sterile in a white, low density polyethylene (LDPE) bottle with a controlled dropper tip and a tan, with the size 5 mL in an 10 mL bottle. Price 30 L.E

27. Competitors

28. The 1st and the only available Moxifloxacin in the market (Till 6 /2010)is : Vigamox Price 45L.E

29. So,, what is new in our hands??

30. BenzalkoniumChloride..is it valuable? 1- BAK is active against bacteria, some viruses, fungi and protozoa. 2- Enhances medication's absorption rate. 3- In some cases increases the speed of microbial killing. 4- Prevents contamination of the content of the bottle.

31. Biocidal action of Benzalkoniumchloride 1- BAK causes dissociation of cellular membrane lipid bilayers, which compromises cellular permeability controls and induces leakage of cellular contents. 2- BAK Deactivates Enzymes, which finely control a wide range of respiratory and metabolic cellular activities.

32. Benzalkonium chloride tolerability In the patient with mild to moderate dry eye, BAK preserved solutions are usually well tolerated when used 4-6 times a day or less.

33. Market Analysis

34. VigamoxSales In 2009 ( Units )

35. Total 2009 sales were: 151,837 unit

36. VigamoxSales 2007 - 2009 ( Units )

38. How to compete?!

39. Mograflox®is the 1st Moxifloxacin 0.5% solution containing a preservative (Benzalkonium Chloride 0.01%) 1 BAK

40. Mograflox®is a high quality product with an affordable price, as patients can use the whole bottle with no fear of contamination with only 30 L.E. / bottle 2 Price

41. Mograflox® is a normal continuation for our successful R&D department sticking to the role of creating what the market really needs. 3 Beta pharma is serving for patients’ sake

42. Now it’s your turn Thanks ;)